Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS)...
Posted: 2010-07-29 03:00:00
More from this author:
Multiple Sclerosis: What Part Do Relapses Play In Severe Disability?
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Multiple Sclerosis Relapses and Severe Disability
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Neuronal and BBB damage induced by sera from patients with secondary progressive multiple sclerosis.
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Stress, Fear, Anxiety and MS
From the Web > About.com Multiple Sclerosis: Most Popular Article
From the Web > About.com Multiple Sclerosis: Most Popular Article
Puusepp's sign—Clinical significance of a forgotten pyramidal sign
From the Web > MedWorm: Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
Related Articles:
Granulocyte-macrophage colony-stimulating factor antibody suppresses microglial activity: implications for anti-inflammatory effects in Alzheimer's Disease and multiple sclerosis
From the Web > MedWorm: Multiple Sclerosis
Shop online at your favourite stores and support the MS Trust
From the Web > MedWorm: Multiple Sclerosis
JAX publishes online tool for exploring autoimmune disease gene networks
From the Web > MedWorm: Multiple Sclerosis
Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis
From the Web > MedWorm: Multiple Sclerosis
Guidelines Issued for Self-Management in Multiple Sclerosis
From the Web > MedWorm: Multiple Sclerosis
